Expertise in
22
conditions

Dr. Bret E. Friday

Hematology
Essentia Health-Duluth Clinic 1st Street (Building A)
420 E 1st St, 
Duluth, MN 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
Essentia Health-Duluth Clinic 1st Street (Building A)
420 E 1st St, 
Duluth, MN 

Overview

Bret Friday is a Hematologist practicing medicine in Duluth, Minnesota.

Dr. Friday is highly rated in 22 conditions, according to our data. His clinical expertise encompasses ALK-Positive Non-Small Cell Lung Cancer, Small Lymphocytic Lymphoma (SLL), Multiple Myeloma, Smoldering Multiple Myeloma, and Endoscopy.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 118 clinical trials. Dr. Friday is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MN

Hospital Affiliations

Essentia Health Virginia
Rainy Lake Medical Center
Essentia Health Northern Pines Medical Center
Essentia Health Duluth
St Marys Hospital Superior

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford Health
  • HMO
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Essentia Health-Duluth Clinic 1st Street (Building A)
420 E 1st St, Duluth, MN 55805
Other Locations
Essentia Health-Virginia Clinic
1101 9th St N, Virginia, MN 55792

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

115 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Procedure
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: October 31, 2024
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Essentia Health-Duluth Clinic 1st Street (Building A)

420 E 1st St, 
Duluth, MN 
 (0.1 miles away)
218-212-8447
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Nikcevich is a Hematologist practicing medicine in Duluth, Minnesota. Dr. Nikcevich is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Large-Cell Immunoblastic Lymphoma, Richter Syndrome, and Chronic B-Cell Leukemia (CBCL). Dr. Nikcevich is currently accepting new patients.

Expertise in
33
conditions
Dr. Homam Alkaied
Hematology | Oncology
Expertise in
33
conditions
Dr. Homam Alkaied
Hematology | Oncology
Referral may be required

Office

1001 E Superior St Ste L101, 
Duluth, MN 
 (4.1 miles away)
218-249-3081
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Homam Alkaied is a Hematologist and an Oncologist practicing medicine in Duluth, Minnesota. Dr. Alkaied is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Multiple Myeloma, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Alkaied is currently accepting new patients.

Expertise in
12
conditions
Dr. Roberto J. Fernandez
Hematology | Oncology
Expertise in
12
conditions
Dr. Roberto J. Fernandez
Hematology | Oncology
Referral may be required

St Luke's Nephrology Associates

1001 E Superior St, 
Duluth, MN 
 (0.5 miles away)
218-249-3081
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Roberto Fernandez is a Hematologist and an Oncologist practicing medicine in Duluth, Minnesota. Dr. Fernandez is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), Neuroendocrine Tumor, and Chronic Lymphocytic Leukemia (CLL). Dr. Fernandez is currently accepting new patients.

Frequently Asked Questions about Dr. Bret E. Friday

How do I make an appointment with Dr. Bret E. Friday?

You can book an appointment with Dr. Bret E. Friday by calling their office at 218-288-1914. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bret E. Friday a top-rated expert for ALK-Positive Non-Small Cell Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bret E. Friday is classified as an Distinguished expert for ALK-Positive Non-Small Cell Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bret E. Friday specialize in?

While Dr. Bret E. Friday is a Hematology, they have specific expertise in ALK-Positive Non-Small Cell Lung Cancer, Small Lymphocytic Lymphoma (SLL), and Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Bret E. Friday participate in research or clinical trials?

Yes. Dr. Bret E. Friday has published 11 articles and abstracts on conditions like ALK-Positive Non-Small Cell Lung Cancer. You can view a list of Dr. Bret E. Friday's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bret E. Friday accept my insurance?

Dr. Bret E. Friday accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 218-288-1914 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Friday's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile